SCHEMBL600955

SCHEMBL600955

CCOC(=O)c1c(N)n[nH]c1C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.71
SMN1; SMN2 Q16637 5/20 0.56
HTT P42858 3/20 0.56
MAPK10 P53779 2/20 0.56
KDM4E B2RXH2 6/20 0.54
MAPT P10636 5/20 0.54
KMT2A Q03164 3/20 0.54
POLB P06746 1/20 0.54
ALDH1A1 P00352 7/20 0.50
HPGD P15428 5/20 0.50
GAA P10253 3/20 0.50
MEN1 O00255 1/20 0.46
RECQL P46063 1/20 0.46
FHIT P49789 1/20 0.46
PKM P14618 2/20 0.45
LMNA P02545 1/20 0.45
HSD17B10 Q99714 2/20 0.44
RAB9A P51151 2/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL942577 0.86 PDE4D (0.56) PDE4DSMN1; SMN2HTTMAPK10KDM4E
SCHEMBL11160154 0.84 SMN1; SMN2 (0.55) PDE4DSMN1; SMN2HTTMAPK10KDM4E
SCHEMBL353564 0.83 PDE4D (1.00) PDE4DSMN1; SMN2MAPK10KDM4EMAPT
SCHEMBL17781303 0.83 SMN1; SMN2 (0.53) PDE4DSMN1; SMN2HTTMAPK10KDM4E
SCHEMBL20709978 0.83 SMN1; SMN2 (0.53) PDE4DSMN1; SMN2HTTMAPK10KDM4E
SCHEMBL11472383 0.81 GAA (0.49) PDE4DSMN1; SMN2HTTMAPK10MAPT
SCHEMBL22768839 0.81 SMN1; SMN2 (0.52) PDE4DSMN1; SMN2HTTMAPK10KDM4E
SCHEMBL2084577 0.80 SMN1; SMN2 (0.51) PDE4DSMN1; SMN2HTTMAPK10KDM4E
SCHEMBL7513038 0.80 PDE4D (0.73) PDE4DSMN1; SMN2MAPK10KDM4EMAPT
SCHEMBL31367819 0.80 PDE4D (0.73) PDE4DSMN1; SMN2MAPK10KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0315433-A2 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics A.H. ROBINS COMPANY, INCORPORATED (US) 1989-05-10 EP claimed
US-4826866-A 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics A. H. ROBINS COMPANY, INCORPORATED (US) 1989-05-02 US claimed
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2025-06-12 US disclosed
EP-4536224-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE Blossomhill Therapeutics, Inc. (US) 2025-04-16 EP disclosed
CN-119421709-A Indazole-containing macrocyclic compounds and uses thereof 荣山医药股份有限公司 2025-02-11 CN disclosed
US-12213976-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2025-02-04 US disclosed
CN-114980886-B Compounds and methods for treating oxalate-related diseases 奥沙鲁克斯公司 2024-08-09 CN disclosed
US-11944626-B2 Small molecule inhibitors of ALDH and uses thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-04-02 US disclosed
EP-3471712-B1 SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF UNIV MICHIGAN REGENTS (US) 2024-01-03 EP disclosed
WO-2023240138-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20050256130-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2005-11-17 US disclosed
WO-2005056015-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2005-06-23 WO disclosed
EP-1531822-A1 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS Chemocentryx, Inc. (US) 2005-05-25 EP disclosed
US-20040162282-A1 Substituted piperazines CHEMOCENTRYX, INC. 2004-08-19 US disclosed
US-20040082571-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2004-04-29 US disclosed
WO-2003105853-A1 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS CHEMOCENTRYX, INC. (US) 2003-12-24 WO disclosed
EP-0315433-A2 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics A.H. ROBINS COMPANY, INCORPORATED (US) 1989-05-10 EP disclosed
US-4281000-A Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents AMERICAN CYANAMID COMPANY (US) 1981-07-28 US disclosed
EP-0025819-A1 Substituted pyrazolo (1,5-a) pyrimidines, and their preparation AMERICAN CYANAMID COMPANY (US) 1981-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082571-A1 Substituted piperazines CCR1, CCR3, CCRL2 PDE4D 3600/4885SMN1; SMN2 1035/4885HTT 3106/4885
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE AADAC, PAICS, CYP3A43 PDE4D 1361/4885SMN1; SMN2 2592/4885HTT 1174/4885
US-20050256130-A1 Substituted piperazines CCR1, CCR3, CCRL2 PDE4D 2673/4885SMN1; SMN2 1026/4885HTT 3478/4885
US-11944626-B2 Small molecule inhibitors of ALDH and uses thereof ALDH2, ALDH1A1, ALDH3A1 PDE4D 1846/4885SMN1; SMN2 3775/4885HTT 2698/4885
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT PDE4D 1661/4885SMN1; SMN2 3115/4885HTT 2349/4885
US-20040162282-A1 Substituted piperazines CCR1, CCR3, CCRL2 PDE4D 3600/4885SMN1; SMN2 1035/4885HTT 3106/4885
US-12213976-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, OAT PDE4D 1661/4885SMN1; SMN2 3115/4885HTT 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.